Background and Aims: Novel noninvasive biomarkers with high diagnostic accuracy are required to assess mucosal healing, which is associated with sustained clinical remission, in inflammatory bowel disease. This study aimed to explore sepsis markers as potential biomarkers for mucosal healing. Results: In all, 68 UC patients and 33 CD patients were included in this study. In patients with UC, the sIL-2R level was significantly higher in patients without cMH than in those with cMH. The sIL-2R level had the highest diagnostic value for identifying cMH in UC. In patients with CD, CRP and sCD14-ST levels were significantly higher in patients without cMH than in those with cMH, and both CRP and sCD14-ST had good diagnostic values for identifying cMH. The sCD14-ST level had a high diagnostic value for identifying cMH even among CD patients with complete clinical remission, defined as a Harvey-Bradshaw index of 0. Conclusions: The sIL-2R and sCD14-ST levels in patients with UC and CD, respectively, can be useful surrogate markers for identifying mucosal healing in inflammatory bowel disease.
Introduction

Idiopathic inflammatory bowel diseases, ulcerative colitis [UC] and
Crohn's disease [CD] , are characterised by chronic and relapsing gastrointestinal inflammation with unknown aetiology. Although patients with inflammatory bowel disease have been treated with the goal of achieving clinical remission, recent advanced therapies such as immunomodulators and biologic agents have changed the therapeutic goal from clinical remission to mucosal healing, which is associated with better clinical outcomes. Endoscopic and histological assessments are considered to be gold-standard examination methods for determining the occurrence of mucosal healing. 1, 2 However, the endoscopic procedure is an inconvenient, invasive, and expensive procedure; therefore, clinical, serological, and faecal markers have been used as alternatives for monitoring the activity of the disease. 3 Serum C-reactive protein [CRP] is widely available and a reliable marker for predicting endoscopic activity in inflammatory bowel disease, with high accuracy. 4 Nevertheless, CRP is not always clearly correlated with mucosal activity, especially in UC. 5 Although multiple studies have shown the clinical utility of faecal calprotectin, 4 the low compliance of collecting stool samples and/ or difficulty of collecting diarrhoea samples would frequently disturb clinical monitoring. Therefore, novel blood-based biomarkers with high diagnostic accuracy would be highly useful for detection of mucosal inflammation.
Soluble CD14 subtype [sCD14-ST, presepsin] was recently identified as an early-phase biomarker for sepsis. 6 The plasma concentration of sCD14-ST is correlated with the severity of sepsis 7 and is a predictive factor for the outcome of patients with sepsis.
8 sCD14-ST is an N-terminal fragment of CD14 that is cleaved by elastase after phagocytosis of bacteria and is released from innate immune cells, mainly from monocytes, 9 reflecting innate immune cell activation. In contrast, soluble interleukin-2 receptor [sIL-2R] is produced by lymphocytes 10 under conditions of malignancy and infection, 11 reflecting lymphocyte activation. Recent advances in the understanding of inflammatory bowel disease pathogenesis have demonstrated that the interaction between host genetics and intestinal microbiota can trigger immune responses and cause intestinal inflammation, 12 indicating that immune cell activation markers induced by bacterial components could serve as potential candidates for predicting mucosal inflammation in inflammatory bowel disease. However, to the best of our knowledge, no study has evaluated the association between sCD14-ST and the activity of inflammatory bowel disease. Therefore, this study aimed to assess sepsis markers, including sCD14-ST, as potential biomarkers for detection of mucosal healing.
Materials and Methods
Patients
Patients with UC or CD, who underwent blood tests for CRP and sepsis markers within 2 weeks of colonoscopy or balloon-assisted enteroscopy from January 2016 to August 2016, were retrospectively enrolled for our study at Osaka City University Hospital. Patients diagnosed with concomitant infection, comorbid autoimmune diseases such as collagen disease, malignancy, or renal failure, upon routine screening examinations or based on the patients' symptoms, were excluded. 
Ethical considerations
This study was approved by the ethics committee of Osaka City University Hospital [No. 3522] . The ethics committee granted exemption for written informed consent to this study because the analysis used anonymised clinical data that were retrospectively obtained after each patient agreed to treatment by written consent. Nevertheless, all patients were notified of the content and information in this study and were given the opportunity to refuse participation. None of the patients refused participation. This procedure followed the Ethical Guidelines for Medical and Health Research Involving Human Subjects established by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, in Japan.
Results
Patient characteristics
A total of 101 patients with inflammatory bowel disease were included in this study. The median ages of the 68 patients with UC and 33 patients with CD were 48.0 years and 37.9 years, respectively. The median partial Mayo score for patients with UC was 0 [range, 0-9], and the median HBI for patients with CD was 0 [0-11]. The median MES for patients with UC was 0 [range, 0-3], and the median SES-CD for patients with Crohn's disease was 7 [range, 0-26] . Other characteristics of this study population are shown in Table 1 . The median CRP, PCT, sCD14-ST, and sIL-2R levels are shown in Table 1 .
Relationship between sepsis marker level and clinical activity scores
We first assessed the relationship between sepsis marker level and clinical features. There was no difference in the median CRP, PCT, sCD14-ST, or sIL-2R levels between males and females [Supplementary Figure 1A , available as Supplementary data at ECCO-JCC online]. There was no significant difference between the median CRP, PCT, sCD14-ST, or sIL-2R levels and disease extension, location, or behaviour including perianal involvement [Supplementary Figure 1B -E]. Most patients with UC received only mesalamine therapy, whereas patients with CD in this study received mesalamine, immunomodulators, and/or biologics. Therefore, the relationships between markers and therapies in patients with CD were assessed, but no statistical significance was noted [ Supplementary Figure 2A Figure 1E -H].
Correlation between sepsis marker levels and endoscopic activity
We next assessed the correlation between sepsis marker levels and endoscopic activity. Recent studies have shown that patients with UC and cMH, defined by a Mayo endoscopic score [MES] of 0, have a lower risk of clinical relapse than those with partial mucosal healing, defined by an MES of 1. 17 We therefore compared these markers between patients with cMH and those without cMH. For UC, the level of sIL-2R in patients without cMH was significantly higher than that in patients with cMH [p < 0.05] [ Figure 3D ]; however, no significant differences were found between the levels of CRP, PCT, and sCD14-ST and patients with or without cMH [ Figure 3A -C]. On the other hand, CRP [p < 0.001] and sCD14-ST [p < 0.01] levels in patients with CD lacking cMH, defined as an SES-CD ≥ 1, were significantly higher than those of patients with cMH, defined as an SES-CD = 0 BAE, balloon-assisted enteroscopy; CD, Crohn's disease; CRP, C-reactive protein; HBI, Harvey-Bradshaw index; MES, Mayo endoscopic subscore; n, number; PCT, procalcitonin; pMayo, partial Mayo score; sCD14-ST, soluble CD14 subtype; SES-CD, simple endoscopic score for Crohn's disease; sIL-2R, soluble interleukin-2 receptor; UC, ulcerative colitis; VCE, video capsule endoscopy.
[ Figure 3A and C]; however, no significant differences were noted in PCT or sIL-2R levels between patients diagnosed with CD, with or without cMH [ Figure 3B and D]. These results indicated that sepsis markers might serve as novel surrogate markers for predicting cMH in inflammatory bowel disease.
Diagnostic accuracy of sepsis markers for detecting complete mucosal healing
We next performed ROC analysis to assess the predictive capacity of the sepsis markers for identifying patients with cMH. For UC, ROC analysis showed that the level of sIL-2R had the highest predictive value, with an area under the ROC curve of 0.65, whereas CRP, PCT, and sCD14-ST had areas under the ROC curve of 0.54, 0.57, and 0.60, respectively [ Figure 4A ]. Levels of sIL-2R ≤ 274 U/ mL could discriminate cMH from the absence of healing with a sensitivity of 0.600, a specificity of 0. Regarding the clinical situation, it is important to predict cMH among patients who have achieved clinical remission, because clinical remission is not always accompanied by endoscopic remission. 18 Indeed, more than half of the patients with complete clinical remission in our study did not achieve cMH [ Supplementary Figure 3 and C, available as Supplementary data at ECCO-JCC online]. The sCD14-ST level also had the highest predictive value, with an area under the ROC curve of 0.84 [ Figure 4D ]. Levels of sCD14-ST ≤ 89 pg/mL could discriminate cMH from the absence of healing with a sensitivity of 0.857, a specificity of 0.800, a PPV of 0.750, and an NPV of 0.889 [ Table 3 ]. A combination of the sCD14-ST and CRP provided similar discriminatory power compared with sCD14-ST per se [ Table 3 ; and Supplementary Figure 5B ].
Discussion
This is the first report demonstrating the correlation between plasma sCD14-ST and clinical and endoscopic activity of inflammatory bowel disease. We demonstrated a positive correlation between serum sIL-2R level and disease activities in UC, and the higher diagnostic value of sIL-2R for discriminating cMH than that of CRP. We also demonstrated positive correlations between plasma sCD14-ST levels and the clinical and endoscopic disease activity of patients with CD. Furthermore, sCD14-ST could identify cMH with a higher diagnostic value compared with that of CPR in patients with CD showing complete clinical remission. Recent advances in understanding and evaluating the clinical course of inflammatory bowel disease, and advances in therapies, have changed the therapeutic goal from clinical remission to mucosal healing. The discrepancy between clinical and endoscopic activity have been widely recognised; therefore, it is important to assess mucosal inflammation even in patients showing no symptoms. Although multiple blood-based biomarkers, such as acute phase reactants, 3 microRNAs, 19 stool markers, 4 and urine markers, 3 have been reported, CRP is still the most widely available test used in routine clinical practice as an alternative to endoscopy.
PCT, which can be produced in response to bacterial products and proinflammatory cytokines, has been shown to be a useful marker for detecting and evaluating the severity of sepsis and infection. 20 Multiple studies have shown that PCT could also function as a specific marker to distinguish bacterial infection from inflammatory diseases such as inflammatory bowel disease. 21 However, several reports have also demonstrated the use of PCT as a surrogate marker indicating the activity of inflammatory bowel disease. 22, 23 Based on these findings, it might be speculated that minor bacteraemia translocated from a mucosal break or gut microbiota dysbiosis could affect the levels of PCT in active inflammatory bowel disease patients. Therefore, we focused on sepsis markers, including: sCD14-ST, a newly established marker for diagnosing and monitoring sepsis 6, 7 that is more sensitive than other sepsis markers under certain conditions; and sIL-2R, a known marker for lymphocytes activated by malignancy and infection. 11 These markers can be measured conveniently, noninvasively, and rapidly. 24 PCT levels in patients with UC or CD were not correlated with clinical or endoscopic activity in our study. One possible reason for the discrepancy between our data and those from other studies 22, 23 is differences in disease activity. PCT might be insufficient to distinguish cases of very mild inflammation from complete mucosal healing in our study, where patients with relatively mild disease were enrolled. This suggests that PCT is not sufficient for detection of mild inflammation in intestinal mucosa. For patients with UC, only the serum sIL-2R level was correlated with clinical and endoscopic activity [ Figure 1D and E], consistent with previous reports describing sIL-2R in inflammatory bowel disease, 25 and was not correlated with CRP, PCT, or sCD14-ST. CRP is known to not always be correlated with mucosal activity, especially in patients with UC. 5 This can be explained by the main site of inflammation: inflammation is mainly limited to the mucosa in UC, whereas transmural inflammation predominantly occurs in CD. Genetic polymorphisms in CRP have also been reported to influence the variation of CRP concentrations. 26 On the other hand, a recent meta-analysis study described the usefulness of CRP as a biomarker for detecting endoscopic activity in patients with UC. 4 Difference in disease severity between the study populations might explain the discrepancy between our data and those from the meta-analysis. An optimal CRP cut-off value to predict endoscopic active in the metaanalysis was 5 mg/dL, whereas an optimal cut-off value of 0.03 mg/ dL was obtained in our study [ Table 2 ]. In fact, most of the patients in our study had an MES of 0 to 1, indicating that inflammation was limited to mucosa, which is relatively milder disease than in other studies.
The superior clinical outcome of patients with UC showing cMH, defined by an MES of 0, 17 has been set as a clinical goal in therapeutic management. We, therefore, compared the sIL-2R levels between patients with cMH and those without cMH. The sIL-2R levels in patients with cMH were significantly lower than those without cMH, indicating that sIL-2R could be a candidate biomarker for cMH in UC. In analysing the performance of biomarkers for detecting cMH, the sIL-2R level had a higher predictive value, with an area under the ROC curve of 0.65, than that of other markers [ Figure 4A ]. The level of sIL-2R might reflect inflammation caused by UC more sensitively than CRP, even if the inflammation is limited to the mucosa. However, the diagnostic accuracy for detecting cMH using serum sIL-2R level remains lower than that of stool or tissue markers which can be directly affected by mucosal inflammation, such as histological scores, the inflammatory cytokines in inflamed mucosa, and stool markers.
Regarding CD, serum CRP and sIL-2R levels were correlated with both clinical and endoscopic severity [ Figures 1E, H, H], which is consistent with data from previous studies. 4, 27 The CRP levels, but not sIL-2R levels, were lower in patients with an SES-CD of 0 [cMH] compared with those with an SES-CD of one or more. In analysing the performance of biomarkers for detecting cMH, CRP level had an excellent predictive value, with an area under the ROC curve of 0.92 [ Figure 4B ]. In addition, sCD14-ST was correlated with both clinical and endoscopic severity [Figures 1G and 2G] and had a good predictive value, with an area under the ROC curve of 0.85-similar to that of CRP [ Figure 4B ]. These data suggest that CD14-expressing immune cells, such as macrophages, may play a more important role in the pathogenesis of CD 28 than of UC. Clinicians sometimes face IBD patients with clinical remission who still have active lesions endoscopically, because clinical remission is not always accompanied by endoscopic healing. 18 Reliable biomarkers are needed to assess mucosal inflammation in patients with clinical remission showing the absence of endoscopic mucosal healing; therefore, we evaluated the predictive values of sepsis markers for complete mucosal healing among patients with CD showing complete clinical remission. The sCD14-ST levels, but not CRP, in CD patients without cMH were significantly higher than those in patients with cMH [Supplementary Figure 4B and C]. The ROC evaluation showed that the level of sCD14-ST had the highest predictive value, with an area under the ROC curve of 0.84 [ Figure 4D ], and discriminated cMH from the absence of healing with a sensitivity of 0.857, a specificity of 0.800, a PPV of 0.750, and an NPV of 0.889 [ Table 3 ]. This indicated that plasma sCD14-ST in CD patients, even in those with clinical A B remission, could be a potential surrogate biomarker for predicting cMH. The plasma sCD14-ST has the merit of easier sample collection and faster measurement using the CLEIA method, compared with stool-based markers such as faecal calprotectin, whose clinical utility have been showed by multiple studies. At the same time, haemophagocytic syndrome, which can occur after autoimmune diseases or malignancy and renal failure, 29 could cause false-positive results, and agranulocytosis 30 could cause false-negative results; therefore, we excluded patients with comorbid autoimmune disease, malignancy, or renal failure. Although seven CD patients in this study were treated with immunomodulators, which could cause agranulocytosis, none of them had agranulocytosis.
Our study has some limitations. First, this study is a retrospective study and employed a relatively small cohort. Patients who did not undergo blood testing of all markers within 2 weeks of endoscopy were excluded, which might result in selection bias. Second, our study did not investigate faecal calprotectin nor involve histological examination. Finally, not all patients underwent extensive screening tests, including a urine test, chest X-ray, computed tomography, and magnetic resonance imaging, to exclude concomitant infection including perianal abscess, within 2 weeks of colonoscopy. Further prospective studies are needed to clarify these problems and validate the present findings.
In conclusion, serum sIL-2R in patients with UC and plasma sCD14-ST in patients with CD could be potential surrogate biomarkers for detecting cMH. These findings should be validated in further studies.
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